CASI Pharmaceuticals Inc CASI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CASI is a good fit for your portfolio.
News
-
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS
-
CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP
-
CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company
-
CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He
-
CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)
-
CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS
Trading Information
- Previous Close Price
- $6.63
- Day Range
- $6.50–6.68
- 52-Week Range
- $1.90–8.48
- Bid/Ask
- $5.52 / $6.67
- Market Cap
- $88.45 Mil
- Volume/Avg
- 18,752 / 242,258
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.05
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.31%
Company Profile
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 243
Competitors
Valuation
|
Metric
|
CASI
|
PFE
|
|---|---|---|
Price/Earnings (Normalized) | — | 21.47 |
Price/Book Value | 5.72 | 1.89 |
Price/Sales | 3.05 | 3.15 |
Price/Cash Flow | — | 20.25 |
Price/Earnings
CASI
PFE
Financial Strength
|
Metric
|
CASI
|
PFE
|
|---|---|---|
Quick Ratio | 3.01 | 0.67 |
Current Ratio | 5.05 | 1.05 |
Interest Coverage | — | −0.26 |
Quick Ratio
CASI
PFE
Profitability
|
Metric
|
CASI
|
PFE
|
|---|---|---|
Return on Assets (Normalized) | −36.58% | 3.77% |
Return on Equity (Normalized) | −97.49% | 8.51% |
Return on Invested Capital (Normalized) | −56.29% | 5.75% |
Return on Assets
CASI
PFE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Tcppqyjtbq | Trykx | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Qhsgdkf | Rmdrp | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Rhzskhh | Hlbrsb | $118.7 Bil | |||
| Moderna Inc
MRNA
| Qvnjtxd | Hmy | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Yzryqbw | Vqrzdvl | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Glndkvq | Zwnsl | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Sbvlgnf | Hgf | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Mxmclmnv | Jggsqp | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Dhpfqgdl | Ljzb | $15.0 Bil | |||
| Incyte Corp
INCY
| Jbwpwmbfq | Wrkbjc | $13.5 Bil |